Report : Europe Bioprocessing Market Forecast to 2031 - Regional Analysis - by Product (Instruments and Consumables & Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell & Gene Therapy, and Others), and End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others)
At 13.2% CAGR, Europe Bioprocessing Market is Projected to be Worth US$ 16,803.47 Million by 2031, says Business Market Insights
According to Business Market Insights' research, the Europe bioprocessing market was valued at US$ 6,216.50 million in 2023 and is expected to reach US$ 16,803.47 million by 2031, registering a CAGR of 13.2% from 2023 to 2031. Proliferating demand for personalized medicine and growing biopharmaceutical industry are among the critical factors attributed to drive the Europe bioprocessing market growth.
The transformation of the healthcare industry from one-size-fits-all to a targeted approach is expanding the demand for personalized medicine. Precision medicine is being considered as one of the most promising approaches to tackle health concerns such as cancer, neurodegenerative diseases, and rare genetic conditions. Innovations in the production of personalized medicines are likely to impact the entire sector, and single-use technologies aimed at smaller-volume production have potential applications in protein bioproduction, particularly in downstream processes. Personalized and differentiated approaches to medicine are leading to a need for a wider range of products-many of them for a relatively small group of patients. Therefore, a fundamentally different approach to the production and delivery of biological products may be required. Precision medicine utilizes the genomic information of an individual to offer targeted treatment for a particular indication. The growing number of orphan diseases has increased the demand for biologics and drugs, which has subsequently boosted the growth of personalized medicines. In 2019, the FDA approved ~12 personalized medications for addressing the root causes of disease and further integrated precision medicine with clinical care. Also, increasing government efforts are strengthening personalized medicine research activities. For instance, in February 2020, the National Human Genome Research Institute (NHGRI) announced to establish a new precision medicine and genomics program. This program focuses on the innovation of genomics and informatics tools for better diagnosis and treatment of disease. Personalized medicines leverage advances in genetics and bioinformatics to target specific patient populations and treat previously untreatable diseases. Personalized medicine uses bioprocessing techniques to develop tailored therapies. From isolating specific cells to developing patient-specific treatments, bioprocessing steps are essential for producing treatments tailored to the patient. Therefore, the rising demand for personalized medicine is predicted to offer significant growth opportunities to the players operating in the bioprocessing market during the forecast period.
On the contrary, stringent regulatory policies and limitations associated with bioprocessing hamper the growth of Europe bioprocessing market.
Based on product, the Europe bioprocessing market is bifurcated into instruments and consumables & accessories. The instruments segment held 67.3% market share in 2023, amassing US$ 4,182.67 million. It is projected to garner US$ 11,709.40 million by 2031 to register 13.7% CAGR during 2023-2031. Furthermore, the instruments segment is sub segmented into filtration devices, bioreactors, chromatography systems, centrifuge, drying devices, and others. Additionally, the bioreactors sub segment is categorized into pilot scale, full scale, and laboratory scale. Furthermore, the sub segment chromatography systems is segmented into liquid chromatography, gas chromatography, and others. Additionally, the consumables & accessories segment is sub segmented into reagents, cell culture media, chromatography resins, and others.
In terms of scale of operation, the Europe bioprocessing market is bifurcated into commercial operations and clinical operations. The commercial operations segment held 82.0% share of Europe bioprocessing market in 2023, amassing US$ 5,096.84 million. It is anticipated to garner US$ 14,183.83 million by 2031 to expand at 13.6% CAGR during 2023-2031.
By process, the Europe bioprocessing market is bifurcated into downstream bioprocess and upstream bioprocess. The downstream bioprocess aids segment held 57.1% share of Europe bioprocessing market in 2023, amassing US$ 3,549.90 million. It is projected to garner US$ 9,822.48 million by 2031 to expand at 13.6% CAGR from 2023 to 2031.
Based on application, the Europe bioprocessing market is categorized into monoclonal antibodies, vaccines, recombinant protein, cell & gene therapy, and others. The monoclonal antibodies segment held 38.3% share of Europe bioprocessing market in 2023, amassing US$ 2,379.11 million. It is predicted to garner US$ 6,015.00 million by 2031 to expand at 12.3% CAGR between 2023 and 2031.
In terms of end user, the Europe bioprocessing market is categorized into biopharmaceutical companies, contract manufacturing organization, and others. The biopharmaceutical companies held 53.4% share of Europe bioprocessing market in 2023, amassing US$ 3,317.06 million. It is estimated to garner US$ 9,097.63 million by 2031 to expand at 13.4% CAGR during 2023-2031.
By country, the Europe bioprocessing market is segmented into Germany, Italy, the UK, France, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 27.1% share of Europe bioprocessing market in 2023. It was assessed at US$ 1,685.29 million in 2023 and is likely to hit US$ 4,770.50 million by 2031, registering a CAGR of 13.9% during 2023-2031.
Key players operating in the Europe bioprocessing market are Getinge AB, Thermo Fisher Scientific Inc, Sartorius AG, Corning Inc, Bio-Rad Laboratories Inc, Merck KGaA, 3M Co, Eppendorf SE, Repligen Corp, Entegris Inc, Agilent Technologies Inc, and Cytiva US LLC, among others.
- In August 2023, To combine Repligen XCell ATF upstream intensification technology into Sartorius' Biostat STR bioreactor, Sartorius AG and Repligen launched an integrated bioreactor system. According to both firms, the objective is to make the deployment of N perfusion and intensified seed train easier for biopharmaceutical makers.
- In March 2023, Corning Inc and Curia have partnered to develop and expedite continuous-flow manufacturing and development programs for the chemical and biopharmaceutical sectors worldwide. The first installation of Corning's G1 production system, intended for the continuous industrial manufacture of active pharmaceutical ingredients, is part of Curia with the Advanced-Flow Reactor team at Corning.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com